<DOC>
	<DOCNO>NCT01037777</DOCNO>
	<brief_summary>The spinocerebellar ataxia ( SCAs ) clinically genetically heterogeneous group autosomal dominantly inherit progressive ataxia disorder . It estimate 30,000 individual European Community directly descend individual affect SCA disorder thus carry 50 % risk inherit SCA mutation . These risk individual provide unique research opportunity prospectively study presymptomatic phase SCA disorder identify early sensitive clinical sign biological marker herald onset illness . This information critical importance development future therapeutic intervention aim postpone clinical onset ataxia . We therefore propose perform prospective observational study individual risk common SCA disorder , SCA1 , SCA2 , SCA3 SCA6 ( RISCA ) . It aim answer follow question : ( 1 ) What incidence disease manifestation mutation carrier ? ( 2 ) Which clinical sign precede onset manifest ataxia SCA1 , SCA2 , SCA3 SCA6 ? ( 3 ) What prevalence incidence precede sign ? ( 4 ) Are prevalence incidence precede sign affect genotype , gender , age , estimate time disease manifestation repeat length ? ( 5 ) Does presence certain precede sign predict manifestation ataxia ? ( 6 ) Are MRI alteration precede onset ataxia ? It plan enroll 480 study participant follow regular interval six year . At visit , study participant ask structured interview number predefined clinical sign potentially precede onset ataxia . In addition , follow self-assessment scale apply : Pittsburgh Sleep Quality Index ( PSQI ) , Diagnostic Criteria Restless Legs Syndrome , PatientÂ´s Health Questionnaire ( PHQ-9 ) . All study participant undergo physical examination include Scale Assessment Rating Ataxia ( SARA ) . Study participant perform SCA Functional Composite ( SCA-FC ) comprehensive measure functional capacity base result quantitative test relate gait ( 8m time walk ) , speech ( PATA rate ) hand function ( 9 hole pegboard ) . In subset study participant , record eye movement obtain volumetric MRIs . The study also use collect store blood urine sample proteomic gene expression study . RISCA conduct Ataxia Study Group ( ASG ) . It rely network structure create EUROSCA project .</brief_summary>
	<brief_title>RISCA : Prospective Study Individuals Risk SCA1 , SCA2 , SCA3 , SCA6 , SCA7</brief_title>
	<detailed_description />
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Spinocerebellar Ataxias</mesh_term>
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<criteria>individual risk spinocerebellar ataxia type 1 , type 2 , type 3 , type 6 type 7 ( SCA1 , SCA2 , SCA3 , SCA6 SCA7 ) age 18 50 year old SCA1 , SCA2 , SCA3 SCA7 age 35 70 year old SCA6 clinical sign ataxia ( SARA &lt; 3 ) write consent family member affect presence clinical sign ataxia ( SARA &gt; 3 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>individual risk SCA1 , SCA2 , SCA3 , SCA6 SCA7</keyword>
</DOC>